The abstract is read at the publisher; the summary is JClub's.
In adults with active TNFi-IR psoriatic arthritis, guselkumab plus golimumab did not improve week 24 minimal disease activity versus guselkumab alone (29% vs 22%).
- Why it matters: The study addresses whether adding golimumab to guselkumab improves outcomes in TNFi-IR PsA, where many participants do not respond adequately to tumor necrosis factor inhibitors.
- What they did: Adults with active TNFi-IR PsA were randomized 2:1 to subcutaneous guselkumab 100 mg plus golimumab 50 mg or guselkumab monotherapy every 4 weeks through week 20, assessing week 24 MDA and ACR responses.
- The result: Secondary outcomes favored combination therapy, including higher ACR50 (44% vs 22%) and ACR20/ACR70, and in participants with CRP ≥0.3 mg/dL combination therapy showed higher MDA (32% vs 5%) and ACR50 (55% vs 14%) with no new safety signals through week 36.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.